Tirzepatide has emerged as a groundbreaking therapy for type 2 diabetes, offering promising outcomes. However, the expense of this innovative drug and its supply have become key concerns for patients and healthcare professionals. While tirzepatide has been authorized by regulatory agencies, its expensive nature presents a significant challenge to